Visión generalGráficoPerfilEstadísticas claveBalance generalNoticias
Derivados
TraderScreen

Orion Oyj/  FI0009014377  /

Cboe Europe DXE
08/11/2024  17:24:43 Diferencia +0.35 Volumen Bid17:25:00 Ask17:25:00 Capitalización de mecado Dividendo A. P/E Ratio
45.07EUR +0.78% 57,199
Volumen de negocios: 1.04 millones		 -Volumen de oferta: - -Tamaño/ Volumen/ Formato de Ask: - 4.83 mil millonesEUR 3.59% 29.29
GlobeNewswire 17/07 Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation...
GlobeNewswire 01/07 Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive ...
GlobeNewswire 03/06 Orion is developing the Finnish life science industry in a unique collaboration project
GlobeNewswire 26/01 Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024
GlobeNewswire 08/01 Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ...
GlobeNewswire 05/01 Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patient...
GlobeNewswire 27/12/2023 NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208
GlobeNewswire 15/11/2023 Orion Research Foundation grants EUR 1,112,000 for research in 2024
GlobeNewswire 24/03/2022 Orion is planning to refocus its R&D – in the future focus would be on cancer and pain
GlobeNewswire 18/02/2022 Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU
GlobeNewswire 17/02/2022 Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall surviva...
GlobeNewswire 03/12/2021 ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets...
GlobeNewswire 09/06/2021 Orion’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality...
GlobeNewswire 09/12/2019 Orion presented data on oral levosimendan at the 30th International Symposium on ALS/MND
GlobeNewswire 31/07/2019 U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant pro...
GlobeNewswire 19/06/2019 1,767 Orion Corporation A shares converted into B shares
GlobeNewswire 11/06/2019 Change in Orion Corporation's holding of treasury shares
GlobeNewswire 31/05/2019 2019 American Society of Clinical Oncology (ASCO) Annual Meeting - Darolutamide data presented
GlobeNewswire 21/05/2019 Orion Corporation: Managers' transactions - Eija Ronkainen
GlobeNewswire 17/05/2019 Orion Corporation: Managers' transactions - Riikka Westerlund
GlobeNewswire 13/05/2019 Orion Corporation completed share acquisitions
GlobeNewswire 13/05/2019 ORION CORPORATION: ACQUISITION OF OWN SHARES 13.05.2019
GlobeNewswire 10/05/2019 ORION CORPORATION: ACQUISITION OF OWN SHARES 10.05.2019
GlobeNewswire 09/05/2019 ORION CORPORATION: ACQUISITION OF OWN SHARES 09.05.2019
GlobeNewswire 08/05/2019 ORION CORPORATION: ACQUISITION OF OWN SHARES 08.05.2019